Monografie
Impact of IFN-γ resistance & MAPK inhibition on the immune surveillance of malignant melanoma - relevance for immune-based therapies
- Sprache
-
Englisch
- Identifier
-
1201274095
Thema
Melanoma; Inhibition; Impact
Beteiligte Personen und Organisationen
- DOI
-
10.17185/duepublico/47582
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:55 MEZ
Objekttyp
- Monografie
Beteiligte
- Pieper, Natalia
- Paschen, Annette
Ähnliche Objekte (12)
Molecular basics for T cell resistance of malignant melanoma
Genomic and non-genomic alterations in melanoma contributing to disease progression and therapy resistance
Characterization of HLA class II negative and HLA class II positive subpopulations from melanoma metastases
Impact of BAP1 inactivation on the class-specific DNA methylation pattern in uveal melanoma
Treatment-induced sculpting of melanoma phenotype and immunogenicity – Impact on resistance to CD8 T cells
Role of arenavirus therapy in melanoma
Targeting the H3K4 demethylase KDM5B/JARID1B affects the metabolic landscape and malignant phenotype of melanoma cells
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Individualized proteogenomics of malignant melanoma cell lines and tissues in response to kinase inhibition and immunotherapy
Die Aktivierung des Immunrezeptors RIG-I beeinflusst die T-Zellsensitivität von Melanomzellen : Untersuchung der zugrundeliegenden Mechanismen
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer
Pharmacological inhibition of cytosolic carboxypeptidase 1-mediated deglutamylation by novel low molecular weight inhibitors
Molecular basics for T cell resistance of malignant melanoma
Genomic and non-genomic alterations in melanoma contributing to disease progression and therapy resistance
Characterization of HLA class II negative and HLA class II positive subpopulations from melanoma metastases
Impact of BAP1 inactivation on the class-specific DNA methylation pattern in uveal melanoma
Treatment-induced sculpting of melanoma phenotype and immunogenicity – Impact on resistance to CD8 T cells
Role of arenavirus therapy in melanoma
Targeting the H3K4 demethylase KDM5B/JARID1B affects the metabolic landscape and malignant phenotype of melanoma cells
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Individualized proteogenomics of malignant melanoma cell lines and tissues in response to kinase inhibition and immunotherapy
Die Aktivierung des Immunrezeptors RIG-I beeinflusst die T-Zellsensitivität von Melanomzellen : Untersuchung der zugrundeliegenden Mechanismen
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer
Pharmacological inhibition of cytosolic carboxypeptidase 1-mediated deglutamylation by novel low molecular weight inhibitors
Molecular basics for T cell resistance of malignant melanoma
Genomic and non-genomic alterations in melanoma contributing to disease progression and therapy resistance
Characterization of HLA class II negative and HLA class II positive subpopulations from melanoma metastases
Impact of BAP1 inactivation on the class-specific DNA methylation pattern in uveal melanoma
Treatment-induced sculpting of melanoma phenotype and immunogenicity – Impact on resistance to CD8 T cells
Role of arenavirus therapy in melanoma
Targeting the H3K4 demethylase KDM5B/JARID1B affects the metabolic landscape and malignant phenotype of melanoma cells
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Individualized proteogenomics of malignant melanoma cell lines and tissues in response to kinase inhibition and immunotherapy
Die Aktivierung des Immunrezeptors RIG-I beeinflusst die T-Zellsensitivität von Melanomzellen : Untersuchung der zugrundeliegenden Mechanismen
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer